# Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)

> **NCT05741086** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT05741086
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-15
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05741086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05741086, "Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05741086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*